Because exacerbations are linked to weaker response to IFN-β [3], we administered double-dose (dd) IFN-β during MS flares and during stable periods as a paired control, and further tested paired responses during stable periods with standard-dose (sd) injections. The gene discussed is IFNB1; the disease is myeloid sarcoma.